Vertex Pharmaceuticals
VRTX
1,613 hedge funds and large institutions have $116B invested in Vertex Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 207 funds opening new positions, 638 increasing their positions, 577 reducing their positions, and 127 closing their positions.
63% more first-time investments, than exits
New positions opened: 207 | Existing positions closed: 127
63% more funds holding in top 10
Funds holding in top 10: 16 → 26 (+10)
29% more call options, than puts
Call options by funds: $771M | Put options by funds: $596M
22% more capital invested
Capital invested by funds: $95.8B → $116B (+$20.7B)
11% more repeat investments, than reductions
Existing positions increased: 638 | Existing positions reduced: 577
4% more funds holding
Funds holding: 1,558 → 1,613 (+55)
1.72% more ownership
Funds ownership: 91.83% → 93.55% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.91B |
| 2 |
JP Morgan Chase
New York
|
+$672M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$572M |
| 4 |
Jennison Associates
New York
|
+$347M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$208M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$695M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$294M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$215M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
-$149M |
| 5 |
Edgewood Management
Greenwich,
Connecticut
|
-$146M |
VRTX Hedge Fund Activity: Q1 2025 in Review
1,613 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2025, worth a combined $116B — up 22% from $95.8B a quarter earlier.
Buyers outnumbered sellers: 207 funds opened new VRTX positions and 127 closed out — a net gain of 80 holders — while 638 added to existing stakes and 577 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $1.91B. The largest seller was Fidelity Investments, cutting an estimated $695M.
- 1,613 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2025, up from 1,558 in Q4 2024.
- Funds reported $116B of Vertex Pharmaceuticals stock for Q1 2025, up 22% quarter-over-quarter.
- 207 funds opened new Vertex Pharmaceuticals positions in Q1 2025 and 127 closed out, a net change of +80 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2025 was Capital Research Global Investors, an estimated $1.91B added.
- The largest Vertex Pharmaceuticals seller in Q1 2025 was Fidelity Investments, an estimated $695M sold.
Based on aggregated 13F filings for Q1 2025.